0      0


Durability of Response Among Psoriatic Arthritis (PsA) Patients Using Biological/Targeted Synthetic Disease-Modifying Antirheumatic Drugs (b/tsDMARDs) in the CorEvitas PsA/Spondyloarthritis Registry


‐ Jan 23, 2024 10:00am

Sponsorship: Sponsored by CorEvitas, LLC. And UCB Pharma.

Presenters: Alexis Ogdie (narrating author), Chao Song, Nicole Middaugh, Maya Marchese, Melissa Eliot, Silky W. Beaty, Robert Low, Philip J. Mease

Abstract: This study aimed to describe the durability of treatment response over 24 months following achievement of 50% improvement in the modified American College of Rheumatology response (mACR50), and factors associated with the response, among patients in the CorEvitas Psoriatic Arthritis (PsA)/Spondyloarthritis (SpA) Registry treated with biological/targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs).

Abstract source: Originally presented at ACR 2023